Palo Alto, CA — Nov 27, 2024 — Neuvivo, a late-clinical stage biopharmaceutical company developing a novel immunotherapy platform to treat amyotrophic lateral sclerosis (ALS), today announced that its Chief Medical Officer, Matthew Davis, MD, RPh, will present at the 35th International Symposium on ALS/MND in Montreal, Canada, December 6-8, 2024. The poster will be primarily focused on NP001’s preservation of vital capacity and extended overall survival in patients with innate immune dysfunction. Neuvivo’s management will also be participating in one-on-one partnering meetings throughout the conference.
Presentation Information
Presenter: Matthew Davis, MD, RPh., Chief Medical Officer, Neuvivo
Title: Systemic Innate Immune System Restoration with NP001 for ALS: Preservation of Vital
Capacity and Extended Overall Survival in Patients with Evidence of Innate Immune Dysfunction
Day: Saturday, December 7th
Time: 5:30 – 7:00 PM
Location: Poster Session b - 517b/c
About ALS
ALS is a relentlessly progressive neurodegenerative disease without cure that, over time, takes away a person’s muscle function and impacts their ability to walk, talk, eat and — ultimately — breathe. Even with available treatments, the current life expectancy of a person with ALS is about 2-5 years after symptoms appear, with death usually resulting from respiratory failure.1 There are currently no medicines available for ALS that preserve breathing function or extend life by more than 2-3 months. Approximately 30,000 adults in the US are living with ALS,2 and 1 in 300 people will be diagnosed in their lifetime.3
About NP001
NP001 is a transformative, investigational therapy that could become the first immunotherapy for ALS designed to restore balance within a dysfunctional innate immune system where pro- and anti-inflammatory processes are no longer in equilibrium. By regaining balance in this natural process, NP001 may help slow the progression of ALS and the loss of skeletal muscle function, including the diaphragm. To date, no other therapy has been able to preserve lung function. If approved, NP001 would be the first disease-modifying treatment with this novel mechanism of action and potentially have a meaningful effect on the lives of patients with ALS.
NP001 has been granted Orphan Drug and Fast Track Designations by the US Food and Drug Administration (FDA) and is eligible for Accelerated Approval and Priority Review, which could shorten the time to a potential approval. A New Drug Application (NDA) for NP001 in ALS is expected to be filed by the end of 2024.
Prior studies established that NP001 is generally safe and well tolerated.
About Neuvivo
Neuvivo is a private, late-clinical stage biopharmaceutical company dedicated to creating and delivering advanced treatments for ALS and other neurodegenerative diseases. Neuvivo has developed a proprietary platform that includes a patented formulation for NP001 and its manufacture. For more information, please visit www.Neuvivo.com.
Media Contacts:
Medical Information Requests:
Kirsti Hastings medinfo@neuvivo.com
Kirsti.Hastings@FGSGlobal.com
(646) 284-6021
Stephanie Blank
Stephanie.Blank@FGSGlobal.com
(917) 593-2907
